Výsledky vyhledávání - "Ageliki, Rapti"

Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study

Autor: George Blazoyiannakis, John Souglakos, X. Tsiafaki, E. Papadakis, Ageliki Rapti, Sophia Agelaki, Helen Bania, Nikos Androulakis, Charalambos Kouroussis, Vassilis Georgoulias, Kostas Kalbakis

Publikováno v: Lung Cancer. 34:77-80

Objective: A phase II study was conducted to evaluate the efficacy and toxicity of vinorelbine–carboplatin (VNB–C) combination as a salvage treatment in patients with advanced non-small cell lung cancer (NSCLC) progressing after or failing previo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42432ddb04ba2c93351900acc3902212
https://doi.org/10.1016/s0169-5002(01)00387-7

Zobrazit plný text záznamu

Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial

Autor: George Samonis, Th. Giannakakis, M. Veslemes, E. Papadakis, J. Vlachonikolis, V. Georgoulias, D. Mavroudis, Th. Grigoratou, S. Kakolyris, Ch. Kouroussis, Ageliki Rapti, Ph. Palamidas, A. Alexopoulos, X. Tsiafaki

Publikováno v: Lung Cancer. 34:47-51

The study compares docetaxel plus cisplatin (DC) and docetaxel plus gemcitabine (DG) regimens for the treatment of advanced non-small cell lung cancer (NSCLC). Patients were randomized to receive either the DC or the DG combination. They were stratif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b6f16e5f160b7deed25fd5a94ae2e1c
https://doi.org/10.1016/s0169-5002(01)00417-2

Zobrazit plný text záznamu

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

Autor: E. Papadakis, A. Alexopoulos, X. Tsiafaki, V. Georgoulias, M. Veslemes, Ph. Palamidas, Ageliki Rapti, I Vlachonikolis

Publikováno v: The Lancet. 357:1478-1484

Summary Background Docetaxel in combination with cisplatin or gemcitabine are active chemotherapy reigimes against non-small-cell lung cancer. We compared the efficacy and safety of a combination of cisplatin and docetaxel (group 1) with that of gemc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93bf6b6c30b9f5425a9dd77f9904ba31
https://doi.org/10.1016/s0140-6736(00)04644-4

Zobrazit plný text záznamu

Plný text ve formátu HTML

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study

Autor: X. Tsiafaki, E. Papadakis, Sophia Agelaki, Ageliki Rapti, Nikos Androulakis, C. Kalofonos, N. Vardakis, E. Bania, Ch. Kouroussis, V. Georgoulias, E. Sarra, M. Toubis, Kyriakos Chainis, S. Kakolyris

Publikováno v: Lung Cancer. 32:179-187

Background: Docetaxel in combination with gemcitabine is an active front-line chemotherapy regimen against non-small cell lung cancer (NSCLC) with acceptable toxicity. A multicenter phase II study was conducted in order to determine the toxicity and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80bb63b092ce0f4ef1cb4eca41386d87
https://doi.org/10.1016/s0169-5002(00)00212-9

Zobrazit plný text záznamu

Vinorelbine-Based Regimens as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer: Two Parallel Multicenter Phase II Trials

Autor: E. Sarra, Sophia Agelaki, X. Tsiafaki, E. Papadakis, Nikos Androulakis, Kostas Kalbakis, Vassilis Georgoulias, Helen Bania, Charalambos Kouroussis, George Blazoyiannakis, Adriani Harpidou, John Souglakos, Ageliki Rapti

Publikováno v: Oncology. 60:235-241

Two parallel phase II trials were conducted in order to evaluate the efficacy and toxicity of vinorelbine-ifosfamide (VNB-IFX) and vinorelbine-carboplatin (VNB-C) combinations as salvage treatment in patients with advanced non-small cell lung cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b1ed275212f01f5e1193edfcd9b3c8
https://doi.org/10.1159/000055324

Zobrazit plný text záznamu

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

Autor: P. Papakotoulas, Aleka Gerogianni, Ageliki Rapti, Georgia Pavlakou, Vassilis Georgoulias, Vassilis Chandrinos, Athanasios G. Pallis, C. Christophyllakis, A. Agelidou, Sofia Agelaki, Ioannis Varthalitis

Publikováno v: Lung cancer (Amsterdam, Netherlands). 65(2)

Objectives To compare the efficacy and safety profile of irinotecan (I) versus the combination of irinotecan/gemcitabine (IG) as second-line treatment of patients with extensive stage small-cell lung cancer (SCLC). Treatment Patients with SCLC who ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4318f3b430a83a984bada7c783856269
https://pubmed.ncbi.nlm.nih.gov/19100647

Zobrazit plný text záznamu

Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study

Autor: Antonia Kalykaki, M. Agelidou, John Varthalitis, Ageliki Rapti, Vassilis Georgoulias, Nikolaos Tzanakis, Kyriakos Chainis, Ioannis Nikolakopoulos, A. Agelidou, Ioannis Stergiou

Publikováno v: Lung cancer (Amsterdam, Netherlands). 49(2)

Summary Purpose: To evaluate the efficacy and toxicity of the gemcitabine plus vinorelbine combination in pretreated patients with small cell lung cancer (SCLC). Patients and methods: Thirty-five pretreated patients (median age 59 years, PS: 0–1 in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f968bbc2c9c30d2f0c39bd147501d72
https://pubmed.ncbi.nlm.nih.gov/16022918

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání